PFS 1
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
J Capdevila, S Tafuto, M Krogh, A Teulé, R Garcia-Carbonero, H-J Klümpen, B Cremer, I Sevilla, B Eriksson, E Tabaksblat, J-P Metges, N S Reed, J Schrader, V Navarro, V Valentí, J Hernando, A M Colao, L Vestermark, C Carnaghi, U P Knigge, P Jimenez-Fonseca, M Benavent, J de Vos-Geelen, M Venerito, A Von Werder, H Jann, A Rinke, D Smith, D Hörsch, N Starling, P Ruszniewski, E Baudin, F-X Caroli-Bosc, J L Manzano, M Martín, A Scarpa, R T Lawlor, C Ragulan, H Ps, A Sadanandam, A Carmona-Bayonas, R Salazar
ESMO Open 10(12) 105922
BACKGROUND: Everolimus or streptozotocin plus 5-fluorouracil (STZ/5-FU) are approved treatments for patients with pancreatic neuroendocrine tumors (panNETs). The SEQTOR trial aimed to assess the optimal treatment sequence. PATIENTS AND METHODS: SEQTOR was an international, open-label, randomized, crossover, phase III trial that recruited adults with unresectable or metastatic, advanced, well-differentiated panNET. Patients received 10 mg/day of everolimus followed upon progression by STZ/5-FU; or the reverse sequence. The primary endpoint was the 35-month progression-free survival (PFS) rate after first- and second-line treatment; however, due to slow accrual and longer survival, it was changed to the 12-month PFS rate following first-line treatment (12-mPFS1). RESULTS: Patients were randomized to everolimus (n = 72) or STZ/5-FU (n = 69) first. The 12-mPFS1 was 71.4% [95% confidence interval (CI) 59.4% to 81.6%] and 61.8% (95% CI 49.2% to 73.3%) (odds ratio 0.65, 95% CI 0.32-1.32) with a median PFS1 of 19.4 versus 22.7 months for everolimus and STZ/5-FU, respectively. STZ/5-FU achieved a significantly higher overall response rate in first-line (11.6% versus 30.3%, P = 0.012) and second-line (30.6% versus 9.1%, P = 0.072) treatments. No differences were shown in overall survival (median 61.7 versus 50.6 months in everolimus first and STZ/5-FU first, respectively; hazard ratio 1.43, 95% CI 0.86-2.37). Discontinuations of everolimus were more frequent. CONCLUSION: STZ/5-FU and everolimus were not statistically different in PFS rates, but STZ/5-FU achieved higher response rates.
1 个 Figure · 3 个 KM 面板
Figure 2 Survival outcomes in arm A (everolimus followed by STZ/5-FU) and arm B (STZ/5-FU followed by everolimus). (A) Kaplan–Meier analysis of progression-free survival (PFS) to first treatment (PFS 1 ). (B) Multivariable hazard analysis of PFS 1 to first treatment assigned in selected subgroups. (C) Kaplan–Meier analysis of PFS to second treatment (PFS 2 ). (D) Multivariable hazard analysis of PFS 2 to first treatment assigned in selected subgroups. (E) Kaplan–Meier analysis of overall survival. (F) Multivariable hazard analysis of OS in selected subgroups. The gold dots and error bars represent the HR and 95% CIs. 5-FU, 5-fluorouracil; CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group performance status; Eve, everolimus; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; STZ, streptozotocin.
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel C
Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel E
Panel E 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。